Human immunodeficiency virus type 1 circulates in vivo as a mixture of heterologous populations (quasispecies). We previously analyzed the quasispecies of the third hypervariable region (V3) in the viral envelope glycoprotein gpl20 in an infected individual and found that the species with a basic amino acid substitution (lysine for aspartic acid) at a particular position evolved and became a distinct population within a short period, followed by progression to the typical immunodeficiency stage (S. Oka et al., AIDS Res. Hum. Retroviruses 10: [271][272][273][274][275][276][277] 1994). In the present study, we examined the biological significance of this amino acid substitution by constructing recombinant viruses with specific point mutations and comparing their replication capabilities in different cell types. The results demonstrated that the single basic amino acid substitution was In a previous study, we have analyzed sequence changes of the V3 domain of HIV-1 in serum samples of a patient, which were obtained at four different times during the clinical course, which was characterized by rapid progression to AIDS and death within 8 months (26). We have also demonstrated striking temporal fluctuations of the viral quasispecies in this patient. Perhaps the most notable finding is that the sequence with a basic substitution, lysine for aspartic acid at position 323, one of the four key positions relevant to cell tropism and 7689 on July 4, 2020 by guest

We previously described a Sendai virus (SeV)-based expression system for the recombinant gp120 of HIV-1 subtype B (rgp120-B), which has permitted the production of antigenetically and functionally authentic gp120 at a concentration as high as 6 microg/ml of culture supernatant (Yu D et al.: Genes Cells 1997;2:457-466). Here the same procedure was successfully applied to the production of HIV-1 subtype E gp120 (rgp120-E). The remarkable production of the proteins by the SeV expression system enabled us to use crude culture supernatants for serological and functional studies of gp120s. The immunological authenticity of rgp120-E was verified by patient sera and anti-V3 loop monoclonal antibodies specific for HIV-1 subtypes B and E. CD4-binding properties were corroborated by FACS analyses. The rgp120s were then used in an enzyme immunoassay (rgp120-EIA) to detect antibodies in the sera of HIV-1-infected individuals, and the performance was assessed in comparison with a conventional V3 loop peptide EIA (V3-EIA). The initial evaluation of a serum panel (n = 164) consisting of 76 subtype E and 88 subtype B sera revealed that the rgp120-EIA was nearly 1000-fold more sensitive than the V3-EIA and was able to detect subtype-specific antibody with 100% sensitivity and with a complete correlation with the genotypes, whereas the V3-EIA failed to detect 9 and 24% of the same subtype E and B sera, respectively. Furthermore, a study employing a panel of 28 international sera with known genotypes (HIV-1 subtypes A through F) confirmed the remarkable specificity of this method. An EIA reactivity higher than 1.0 was an unambiguous predictor of HIV-1 subtype E and B infections. The data imply the presence of strong subtype-specific epitopes for antibody bindings to these rgp120s.

Slow-reacting, complement-requiring hemagglutination-inhibiting (HI) antibody was detected in sera from pigs infected with pseudorabies virus; approximately 16 hemolytic units of complement were necessary for the detection of such antibody. Higher HI antibody titers were obtained when antigen and serum were allowed to incubate before addition of complement than when all three components were incubated at the same time. A HI test was developed in which antigen-serum mixtures were incubated at 4 degrees C for 48 h and then with complement at 37 degrees C for 1 h; this gave an improved sensitivity over the previous incubation without complement.